Advertisement


Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Advertisement